Abstract
8-chloro-adenosine (8-Cl-Ado) is currently in phase-I clinical trials for acute myeloid leukaemia and chronic lymphocytic leukaemia (CLL). Previously, we demonstrated that treatment with 8-Cl-Ado leads to diminished ATP levels. We hypothesized that AMP-activated protein kinase (AMPK) signalling would be initiated in these cells, leading to induction of autophagy. AMPK activation and induction of autophagy were demonstrated during preclinical incubations in CLL cells with the analogues. Importantly, we extended similar observations in CLL lymphocytes during an 8-Cl-Ado phase-I trial. In conclusion, 8-Cl-Ado treatment induces autophagy in CLL lymphocytes in vitro as well as in vivo during clinical trial.
Original language | English (US) |
---|---|
Pages (from-to) | 266-271 |
Number of pages | 6 |
Journal | British Journal of Haematology |
Volume | 179 |
Issue number | 2 |
DOIs | |
State | Published - Oct 2017 |
Keywords
- 8-chloro-adenosine
- AMPK
- CLL
- autophagy
- clinical trial
ASJC Scopus subject areas
- Hematology